Please use this identifier to cite or link to this item:
|Title:||Germline genetic testing to predict drug response and toxicity in oncology- Reality or fiction?||Authors:||Soh, T.I.
|Issue Date:||Aug-2011||Citation:||Soh, T.I.,Yong, W.P. (2011-08). Germline genetic testing to predict drug response and toxicity in oncology- Reality or fiction?. Annals of the Academy of Medicine Singapore 40 (8) : 350-355. ScholarBank@NUS Repository.||Abstract:||In addition to 6-mercaptopurine, 5-fluorouracil and irinotecan, the United States Food and Drug Administration (US FDA) has recently recommended label change for tamoxifen, to include pharmacogenetic information on treatment outcome. With the increasing availability of pharmacogenetic testing, on germline as well as somatic mutations, oncologists are now able to identify individuals at risk of severe treatment toxicity or poor treatment response. However, there are still knowledge gaps to fill before rationalised therapy based on pharmacogenetics can be fully integrated into clinical practice. This review provides an overview on the application of pharmacogenetic testing for germ line mutations in oncology to predict response and toxicity.||Source Title:||Annals of the Academy of Medicine Singapore||URI:||http://scholarbank.nus.edu.sg/handle/10635/110816||ISSN:||03044602|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 25, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.